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Gestational diabetes mellitus (GDM) is associated with increased rates of fetal morbidity and mortal-
ity, both during the pregnancy and in the postnatal life. Current treatment of GDM includes diet with or
without medications, but this management is expensive and poorly cost-effective for the health care
systems. Strategies to prevent such condition would be preferable with respect to its treatment. The
aim of this literature review was to evaluate studies reporting the efficacy of the most used approaches
to prevent GDM as well as evidences of efficacy and safety of dietary supplementations. Systematic
literature searches were performed in electronic databases, covering the period January 1983 to April
2014. Randomized controlled clinical trials were included. Quality of the articles was evaluated with the
Jadad scale. We did not evaluate those articles that were already entered in the most recent system-
atic reviews, and we completed the research with the trials published thereafter. Of 55 articles identi-
fied, 15 randomized controlled trials were eligible. Quality and heterogeneity of the studies cannot
allow firm conclusions. Anyway, trials in which only intake or expenditure has been targeted mostly re-
ported negative results. On the contrary, combined lifestyle programs including diet control (orienting
food intake, restricting energy intake) associated with moderate but continuous physical activity ex-
hibit better efficacy in reducing GDM prevalence. The results from dietary supplements with myo-
inositol or probiotics are promising. The actual evidences provide enough arguments for implementing
large-scale, high-quality randomized controlled trials looking at the possible benefits of these new ap-
proaches for preventing GDM.
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Copyright © 2014 Lippincott Williams & Wilkins. UnaGestational diabetes mellitus (GDM) is defined as
an impairment of any degree of glucose tolerance or
as hyperglycemia with either onset or first recogni-
tion during pregnancy. It is common knowledge that
GDM develops when insulin (over)secretion becomes
inadequate for the physiological degree of insulin resis-
tance, ascertained in pregnant women.1y.com | 669
uthorized reproduction of this article is prohibited.
670 Obstetrical and Gynecological SurveyAs reported in the last Cochrane Review, the prev-
alence of GDM is estimated between 1% and 14% of
the population.2 However, figures are changing, and
we cannot estimate exactly its prevalence, namely,
after the introduction of the new criteria of the In-
ternational Association of Diabetes and Pregnancy
Study Groups for GDM diagnosis.3 It could be ex-
pected that the prevalence of GDM will undergo an
increase because of both the introduction of new risk
factors (often recognized in the general population)
and the lowering of thresholds (just a value outside
the cutoff is enough for the GDM diagnosis) requested
for the diagnosis.
Gestational diabetes mellitus is associated with in-
creased rates of fetal morbidity and mortality, both
during the pregnancy and in the postnatal life.4 More-
over, womenwithGDMand their infants are at increased
risk for diabetes mellitus and metabolic dysfunction
later in life.5
Current treatment of GDM includes diet with or
without medications (metformin or insulin). Unfortu-
nately, this management is expensive and poorly cost-
effective for the health care systems, either in the
short-term or in the long-term period.6
Strategies to prevent such condition would be prefer-
able with respect to its treatment. Current approaches
to prevent GDM have focused on lifestyle interven-
tions such as diet and physical activity (PA), whereas
recently, some supplements are emerging as addi-
tional options.
The aim of this literature review was 2 fold: (a) to
evaluate studies reporting the efficacy of the most used
approaches to prevent GDM before and during preg-
nancy as well as (b) to evaluate evidences of efficacy
and safety of inositols and probiotics supplementation
on glucose/insulin homeostasis in pregnancy.METHODS
A literature search was performed in May 2014 in
the MEDLINE electronic database, looking at ran-
domized controlled trials (RCTs) published in the pe-
riod January 1983 to April 2014.
The following search terms, words and combinations
of words, were used: pregnancy, fertility, gestational
diabetes, prevention gestational diabetes, obesity, preg-
nancy outcome, prenatal care, prenatal/antenatal/pre
pregnancy intervention, life-style, exercise/sport, diet,
weight loss, glucose regulation, Inositol, and probiotics.
We found many trials regarding lifestyle, diet, ex-
ercise, and weight loss during pregnancy. We did not
evaluate those articles that were already entered in
the most recent systematic reviews published duringCopyright © 2014 Lippincott Williams & Wilkins. Una2011 and 2012,7–10 while we completed the research
looking at RCTs published thereafter.
The search was limited to articles published in the
English language and that were easily retrievable via
the home library. For inclusion, an article had to be per-
formed in humans and contain original data, whereas data
from animal and in vitro investigations were excluded.
We attempted to obtain hard copies of every article
listed through our own university library or interli-
brary loans.
In the first section, we analyzed the efficacy of the
most common approaches to prevent GDM either be-
fore or during pregnancy, whereas in the second one,
we examined efficacy and safety of inositols or pro-
biotics supplementation on glucose/insulin homeostasis
in pregnancy.
We evaluated the quality of RCTs with the Jadad
method,11 considered reliable for such assessment.12
The parameters considered by this method are the
following:
(1) Was the study described as randomized?
(2) Was the study described as double blind?
(3) Follow-up: adequate (number and reasons for dropouts
and withdrawals described) or inadequate (number or
reasons for dropouts and withdrawals not described)
(4) Generation of the allocation sequence: adequate
(computer-generated random numbers, table of
random numbers…) or inadequate
(5) Double blinding: adequate (taking placebo, or sim-
ilar) or inadequate (not intervened or different)
For each positive answer, 1 point is assigned, the
overall score going from 0 to 5. Studies scoring 3 or
higher were considered of good quality.
Moreover, we filled in the trasparent reporting of
systematic reviews and meta-analyses (PRISMA)
checklist.13
All sources of information were read and evaluated
by one of the authors (G.D.) and later independently
checked by another author (E.P.).RESULTS
A decision tree is reported in Figure 1. Nineteen
RCTs were considered eligible for this review; 1 was
excluded because of duplicate publication,14 and 3
were excluded because these referred to ongoing study
protocols.15–17
Only 1 study pertained to the effects of a prepregnancy
approach (diet and exercise) to prevent GDM,18 5 trials
described the effects of exercise,19–23 1 reported the
effects of dietary counseling,24 and 3 evaluated life-
style intervention.25–27 Moreover, 3 studies repor-
ted supplementation with myo-inositol (MYO),28–30uthorized reproduction of this article is prohibited.
FIG. 1. Decision tree.
671Interventions in Preventing GDM • CME Review Articlewhereas 2 used probiotics.31,32 No study reported the
use of D chiro-inositol (DCI).
The study design, inclusion and exclusion criteria,
Jadad score, as well as the main results of the RCTs
are described in Tables 1 to 5.
EXERCISE, DIET, AND LIFESTYLE
INTERVENTIONS
During the past few decades, obesity has become a
global health challenge. The prevalence of overweight
and obesity among women of childbearing age is rap-
idly increasing.
Maternal obesity and GDM are independently asso-
ciated with perinatal complications, whereas obesity
is an independent risk factor of GDM. The combined
adverse effect of these 2 risk factors on the frequency
of adverse obstetric outcomes is greater than that of
either one alone.33–35
Prepregnancy body size may be a stronger predic-
tor than gestational weight gain (GWG) for adverse
obstetric and perinatal outcomes.8,11,12,36–38 Because
pregnancy is a relatively brief period in life, PA and
diet interventions should optimally be initiated already
before pregnancy and continue after delivery to pre-
vent the development of overt diabetes.
Prepregnancy Interventions
Some studies described a relationship between obesity
and infertility; modest preconception reductions in weight
(5% to 10%) through diet or lifestyle interventions in-
crease spontaneous or assisted reproductive technology
(ART) conceptions and reduce miscarriage rates.39–42
The only RCT18 carried out in the preconceptional
period was done in overweight ⁄obese women undergo-
ing in vitro fertilization with gonadotropin-releasingCopyright © 2014 Lippincott Williams & Wilkins. Unahormone agonist protocols. Women were approached
after their initial medical consultation and randomized
to lifestyle or standard treatment before commencement
of their in vitro fertilization cycle. All dietary and exer-
cise advices were provided by a qualified dietitian.
There was a greater reduction in GWG for lifestyle
intervention (–3.8 ± 3.0 kg, p < 0.001) compared with
standard treatment (–0.5 ± 1.2 kg, p = 0.092). Both the
intervention (–5.3 ± 4.6 cm) and control (–3.5 ± 3.5 cm)
groups had similar reductions in waist circumference.
The overall pregnancy rate was 53% for the interven-
tion and control groups combined. No data are avail-
able on GDM prevalence or pregnancy outcome.
Interventions During Pregnancy
Exercise
The last Cochrane Review evaluated the ef-
fects of physical exercise for pregnant women for
preventing glucose intolerance or GDM.2 Litera-
ture searches were performed by using 3 Trials Reg-
isters, and the searches were unlimited by time up
to April 2012.
Interventions included any type of exercise and life-
style management reported in RCTs and cluster RCTs.
Five articles were included in which women receiving
additional exercise intervention were compared with
those receiving routine antenatal care.
There was no significant difference in GDM inci-
dence (relative risk (RR), 1.10; 95% confidence inter-
val [CI], 0.66 to 1.84) between the 2 study groups, and
none of the 5 trials found significant differences in in-
sulin sensitivity. Babies born to women receiving exer-
cise interventions had a nonsignificant trend to a lower
ponderal index (mean difference (MD), –0.08 g 
100 m3; 95% CI, –0.18 to 0.02).42 No significant
differences were seen in birth weight (MD, –102.87;
95% CI, –235.34 to 29.60), macrosomia (RR, 0.91;
95% CI, 0.68 to 1.22), small for gestational age (RR,
1.05; 95% CI, 0.25 to 4.40), gestational age at birth
(MD, 0.04 weeks; 95% CI, –0.37 to 0.29), or Apgar
score of lower than 7 at the fifth minute (RR, 1.00;
95% CI, 0.27 to 3.65).
After the publication of such meta-analysis, addi-
tional 5 RCTs were published between April 2012
and April 2014.
In the study published by Barakat et al,19 healthy
pregnant women were randomly assigned to either an
exercise group or a control group. Maternal glucose
screen (50 g), GWG, and several pregnancy outcomes
were recorded. The physical conditioning program
was a 35- to 45-minute session performed 3 times
a week, with 2 land aerobic sessions and 1 aquaticuthorized reproduction of this article is prohibited.
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Copyright © 2014 Lippincott Williams & Wilkins. Unaactivity session from the beginning of the pregnancy
to the end of the third trimester. No cases of GDM
were reported, while no differences in GWG were
found between groups. No exercise-related injuries
were experienced during pregnancy.
In the RCT published by Price et al,20 inactive
women were randomized at 12 to 14 weeks’ gestation
to a group that remained sedentary or to a group that
performed aerobic exercise (45- to 60-minute duration,
performed 4 times per week, at moderate intensity).
Gestational diabetes mellitus was slightly less com-
mon among the active group (9.6% vs 12.9% in con-
trols), although absolute numbers (3 vs 4) were too
small to achieve significance.
In the RCT by Ruchat et al,21 women either at low
or at high risk for GDM were randomized between 16
and 20 weeks’ gestation into a low-intensity versus
vigorous-intensity exercise program consisting of walk-
ing sessions 3 or 4 times a week, gradually increasing
time from 25 to 40 minutes per session, associated with
nutritional control.
Capillary glucose responses to exercise were strongly
influenced by an interaction betweenGDM risk, exercise
duration, and exercise intensity. Decreases in glucose
concentrations were observed after 25 (4% [13%]),
35 (21% [12%]), and 40 minutes (15% [18%]) of
walking in the high-risk group. In low-risk women,
decreases in glucose concentrations were significant,
regardless of exercise intensity and duration.
In the RCT by Oostdam et al,22 overweight/obese
women at risk for GDM since the 15th week of ges-
tation were enrolled until 12 weeks after delivery.
Normal cares were compared with an exercise train-
ing program consisting of 60 minutes of aerobic and
strength exercises, 2 times per week. Intention-to-
treat analysis showed that the exercise program did
not reduce maternal fasting blood glucose levels at
24 and 32 weeks of gestation, insulin sensitivity, or
mean glycosylated hemoglobin. No adverse events
(AEs) resulting from the intervention were reported.
In the RCT by Barakat et al,23 healthy women
were randomly assigned to either an exercise in-
tervention or usual care. The exercise program fo-
cused on moderate-intensity resistance and aerobic
exercises 3 times per week, with duration of 50 to
55 minutes per session. The intervention did not re-
duce the risk for developing GDM (odds ratio [OR],
0.84; 95% CI, 0.50 to 1.40).
Diet
A recent systematic review and meta-analysis pub-
lished in 2011 selected RCTs from January 1980 un-
til March 2011 in several electronic databases. Theuthorized reproduction of this article is prohibited.
T
A
B
LE
2
E
xe
rc
is
e
R
C
T
D
es
ig
n,
R
ef
er
en
ce
T
im
in
g
/D
ur
at
io
n
o
f
T
re
at
m
en
t
N
o
.o
f
S
ub
je
ct
s/
Ja
d
ad
’
S
co
re
In
cl
us
io
n
C
rit
er
ia
E
xc
lu
si
o
n
C
rit
er
ia
M
ai
n
F
in
d
in
g
s
O
p
en
la
b
el
1
9
S
in
ce
10
–1
2
w
k
to
38
–3
8
w
k
E
xe
rc
is
e
g
ro
up
:
21
0
E
xe
rc
is
e
<
20
m
in
,3
d
/w
k;
si
ng
le
to
n
un
co
m
p
lic
at
ed
p
re
g
na
nc
y;
no
t
at
hi
g
h
ris
k
fo
r
p
re
te
rm
b
irt
h
A
ny
m
ed
ic
al
co
nd
iti
o
n
th
at
co
ul
d
af
fe
ct
ex
er
ci
se
N
o
ca
se
s
o
f
G
D
M
in
ex
er
ci
se
g
ro
up
vs
3
in
th
e
co
nt
ro
l
g
ro
up
w
er
e
fo
un
d
.
C
o
nt
ro
lg
ro
up
:
21
8
Ja
d
ad
:
3
P
la
n
to
d
el
iv
er
o
u
ts
id
e
th
ei
r
b
ir
th
ce
n
te
r
O
p
en
la
b
el
2
0
S
in
ce
12
–1
4
w
k
to
6
w
k
p
os
tp
ar
tu
m
A
ct
iv
e
g
ro
up
:
31
E
xe
rc
is
e
le
ss
th
an
o
nc
e
p
er
w
ee
k
fo
r
at
le
as
t
th
e
p
as
t
6
m
o
;
si
ng
le
to
n
p
re
g
na
nc
y
at
12
–1
4
w
k;
B
M
I<
39
kg
/m
2
C
hr
on
ic
he
ar
to
r
lu
ng
di
se
as
es
,
po
or
ly
co
nt
ro
lle
d
di
ab
et
es
,
hy
pe
rt
en
si
on
,e
pi
le
ps
y,
hy
pe
rt
hy
ro
id
is
m
,s
ev
er
e
an
em
ia
,
or
th
op
ed
ic
di
se
as
es
,h
is
to
ry
of
pr
em
at
ur
e
de
liv
er
y,
pr
ev
io
us
sm
al
l-f
or
-g
es
ta
tio
na
l-a
ge
in
fa
nt
,
un
ex
pl
ai
ne
d
fe
ta
ld
ea
th
G
D
M
w
as
sl
ig
ht
ly
le
ss
co
m
m
o
n
am
o
ng
th
e
ac
tiv
e
g
ro
up
.
C
o
nt
ro
lg
ro
up
:
31
Ja
d
ad
:
2
O
p
en
la
b
el
2
1
S
in
ce
16
–2
0
w
k
Lo
w
-i
nt
en
si
ty
g
ro
up
:
H
is
to
ry
of
po
ly
cy
st
ic
ov
ar
y
sy
nd
ro
m
e
an
d/
or
G
D
M
,
m
ac
ro
so
m
ia
,d
ia
be
te
s
in
th
e
im
m
ed
ia
te
fa
m
ily
,e
ar
ly
G
W
G
≥9
kg
,p
re
pr
eg
na
nc
y
B
M
I
≥2
5
kg
/m
2
;n
on
sm
ok
er
s;
ag
ed
20
–4
0
y,
re
gu
la
r
pr
en
at
al
ca
re
,
no
ot
he
r
m
ed
ic
at
io
ns
th
an
pr
en
at
al
vi
ta
m
in
s
M
ul
tip
le
p
re
g
na
nc
y;
ch
ro
ni
c
d
is
ea
se
s;
co
nt
ra
in
d
ic
at
io
ns
to
p
ra
ct
ic
e
ex
er
ci
se
C
ap
illa
ry
gl
uc
os
e
re
sp
on
se
s
to
ex
er
ci
se
w
er
e
st
ro
ng
ly
in
flu
en
ce
d
by
an
in
te
ra
ct
io
n
be
tw
ee
n
G
D
M
ris
k,
ex
er
ci
se
du
ra
tio
n,
an
d
ex
er
ci
se
in
te
ns
ity
.D
ec
re
as
es
in
gl
uc
os
e
co
nc
en
tra
tio
ns
w
er
e
ob
se
rv
ed
af
te
r2
5,
35
,a
nd
40
m
in
of
w
al
ki
ng
in
hi
gh
-r
is
k
lo
w
-in
te
ns
ity
gr
ou
p.
In
th
e
hi
gh
-r
is
k
vi
go
ro
us
-in
te
ns
ity
gr
ou
p,
gl
uc
os
e
co
nc
en
tra
tio
ns
de
cr
ea
se
d
si
gn
ifi
ca
nt
ly
on
ly
af
te
r2
5
an
d
35
m
in
an
d
in
cr
ea
si
ng
th
e
ex
er
ci
se
tim
e
at
te
nu
at
ed
gl
uc
os
e
co
nc
en
tra
tio
ns
de
cl
in
e.
In
lo
w
-r
is
k
w
om
en
,r
eg
ar
dl
es
s
of
ex
er
ci
se
in
te
ns
ity
an
d
du
ra
tio
n,
de
cr
ea
se
s
in
gl
uc
os
e
co
nc
en
tra
tio
ns
w
er
e
si
gn
ifi
ca
nt
an
d
si
m
ila
r.
-L
o
w
ris
k
fo
r
G
D
M
:
12
-H
ig
h
ris
k
fo
r
G
D
M
:
11
V
ig
o
ro
us
-i
nt
en
si
ty
g
ro
up
:
-L
o
w
-r
is
k
fo
r
G
D
M
:
12
-H
ig
h-
ris
k
fo
r
G
D
M
:
11
Ja
d
ad
:
3
O
p
en
la
b
el
2
2
F
ro
m
15
w
k
o
f
g
es
ta
tio
n
un
til
12
w
k
af
te
r
d
el
iv
er
y
In
te
rv
en
tio
n:
62
B
M
I≥
30
o
r
B
M
I≥
25
kg
/m
2
an
d
at
le
as
t:
hi
st
o
ry
o
f
m
ac
ro
so
m
ia
o
r
hi
st
or
y
o
f
G
D
M
o
r
fir
st
g
ra
d
e
re
la
tiv
e
w
ith
ty
p
e
2
D
M
R
ec
ru
itm
en
ta
fte
r
20
w
k;
ag
ed
<
18
y;
in
ad
eq
ua
te
kn
ow
le
dg
e
of
th
e
D
ut
ch
la
ng
ua
ge
;G
D
M
be
fo
re
ra
nd
om
iz
at
io
n;
hy
pe
rt
en
si
on
;
al
co
ho
l/d
ru
g
ab
us
e;
us
e
of
an
y
m
ed
ic
at
io
n
th
at
af
fe
ct
in
su
lin
se
cr
et
io
n
or
se
ns
iti
vi
ty
;s
er
io
us
pu
lm
on
ar
y,
ca
rd
ia
c,
he
pa
tic
,o
r
re
na
li
m
pa
irm
en
t;
m
al
ig
na
nt
di
se
as
e;
se
rio
us
m
en
ta
lo
r
ph
ys
ic
al
im
pa
irm
en
t
N
o
di
ffe
re
nc
es
on
G
D
M
di
ag
no
si
s
w
er
e
fo
un
d
be
tw
ee
n
gr
ou
ps
.A
ls
o
th
e
ex
er
ci
se
pr
og
ra
m
di
d
no
tr
ed
uc
e
m
at
er
na
lf
as
tin
g
bl
oo
d
gl
uc
os
e
le
ve
ls
or
in
su
lin
se
ns
iti
vi
ty
at
24
–3
2
w
k.
C
o
nt
ro
l:
59
Ja
d
ad
:
3
O
p
en
la
b
el
2
3
Fr
om
6–
9
w
k
to
38
–3
9
w
k
E
xe
rc
is
e:
40
H
ea
lth
y
w
o
m
en
,
un
co
m
p
lic
at
ed
an
d
si
ng
le
to
n
p
re
g
na
nc
ie
s
A
ny
ty
p
e
o
f
ab
so
lu
te
o
b
st
et
ric
co
nt
ra
in
d
ic
at
io
n
to
p
ra
ct
ic
e
ex
er
ci
se
S
ig
ni
fic
an
td
iff
er
en
ce
s
w
er
e
no
tf
ou
nd
be
tw
ee
n
st
ud
y
gr
ou
ps
in
G
D
M
ca
se
s.
V
al
ue
s
co
rr
es
po
nd
in
g
to
th
e
ex
er
ci
se
gr
ou
p
w
er
e
be
tt
er
th
an
th
os
e
of
th
e
co
nt
ro
lg
ro
up
.
C
o
nt
ro
l:
43
Ja
d
ad
:
2
673Interventions in Preventing GDM • CME Review Article
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
T
A
B
LE
3
D
ie
t
R
C
T
D
es
ig
n,
R
ef
er
en
ce
T
im
in
g
/D
ur
at
io
n
o
f
T
re
at
m
en
t
N
o
.
o
f
S
ub
je
ct
s/
Ja
d
ad
’
S
co
re
In
cl
us
io
n
C
rit
er
ia
E
xc
lu
si
o
n
C
rit
er
ia
M
ai
n
F
in
d
in
g
s
O
p
en
la
b
el
2
4
S
in
ce
th
e
b
eg
in
ni
ng
o
f
p
re
g
na
nc
y
(w
ith
in
18
th
w
k)
In
te
rv
en
tio
n:
37
2
II
G
ra
vi
da
w
ho
pr
ev
io
us
ly
de
liv
er
ed
a
m
ac
ro
so
m
e
(>
40
00
g)
A
ny
m
ed
ic
al
di
so
rd
er
,p
re
vi
ou
s
G
D
M
,
dr
ug
s,
ag
ed
<
18
y,
ge
st
at
io
n
>
18
w
k,
m
ul
tip
le
pr
eg
na
nc
y
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
ex
is
te
d
in
th
e
in
ci
de
nc
e
of
G
D
M
;t
he
ra
te
of
gl
uc
os
e
in
to
le
ra
nc
e
w
as
lo
w
er
in
th
e
in
te
rv
en
tio
n
gr
ou
p.
C
o
nt
ro
l:
38
7
Ja
d
ad
:
2
674 Obstetrical and Gynecological Survey
Copyright © 2014 Lippincott Williams & Wilkins. Unasearch strategy focused on pregnant women and out-
comes related to GDM as well as possible interven-
tions to prevent or treat GDM.9 We consider only
the results about dietary counseling.
Nine studies compared any form of dietary counsel-
ing with usual care; 3 of them showed no statistical dif-
ference in maternal fasting glucose (weighted mean
differences, –0.21; 95% CI, –0.45 to –0.02 mmol/L)
between groups. Seven studies reported the incidence
of GDM. Dietary counseling was more effective than
usual care in reducing the risk for GDM (reducing
the risk, –0.05; 95% CI, –0.10 to –0.01). According
to the authors, the studies were of low quality.
Three trials showed no statistical difference in mater-
nal fasting glucose (weighted mean differences, –0.13;
95% CI, –0.3 to –0.04 mmol/L) between pregnant
women who received low glycemic index diet advice
(carbohydrates that break down more slowly during di-
gestion) and those who received high glycemic index
diet advice (carbohydrates that break down quickly).
Still, this evidence was of low quality.
After this review, only 1 other trial was published.
In this study,24 nondiabetic women who previously
delivered an infant weighing more than 4 kg were
randomized to receive low glycemic index diet early
in pregnancy or no dietary intervention. No significant
differences were found in the incidence of GDM or in
birth weight, whereas the rate of glucose intolerance
was lower in the intervention group. The latter also re-
ported a significantly lower GWG (12.2 vs 13.7 kg;
MD, –1.3; 95% CI, –2.4 to –0.2).Lifestyle Interventions
A systematic review and meta-analyses of RCTs
and non-RCTs on the efficacy of antenatal dietary,
activity, behavior, or lifestyle interventions in over-
weight and obese pregnant women was published in
2012.8 Literature searches were performed using 5 elec-
tronic databases and 8 other databases; the searches
were unlimited by time up to January 2012. Maternal
outcome measures included GWG and GDM.
Thirteen RCTs and 6 non-RCTs were identified
and included in the meta-analysis. The evidence sug-
gests that antenatal dietary and lifestyle interventions
in obese pregnant women reduce GWG (–2.21 kg;
95% CI, –2.86 to –1.59 kg) and suggests a trend to-
ward a reduction in the prevalence of GDM (OR,
0.80; 95% CI, 0.58 to 1.10).
After the publication of these data, we found 3
more RCTs published until April 2014.
In the RCT by Harrison et al,25 pregnant women at
risk for developing GDM were enrolled and allocateduthorized reproduction of this article is prohibited.
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Copyright © 2014 Lippincott Williams & Wilkins. Unato control or to receive an individual 4-session behav-
ior change lifestyle intervention. The sessions pro-
vided pregnancy-specific dietary advices in addition
to simple healthy eating and PA messages. All women
received standard maternal care. At 28 weeks, GDM
prevalence was 22%, with a trend to be lower in the
intervention group (P = 0.1). Gestational weight gain
was significantly lower in the intervention versus con-
trol group (6.0 ± 2.8 kg vs 6.9 ± 3.3 kg).
In the RCT by Petrella et al,26 women with a pre-
pregnancy body mass index (BMI) of greater than
25 were randomized at first trimester to no inter-
vention or a Therapeutic Lifestyle Changes (TLC)
program including diet and mild PA consisting of
30 minutes of moderate-intensity activity at least
3 days a week. Significant changes in eating habits
occurred in the TLC group, which increased the num-
ber of snacks, the intake of fruits and vegetables,
and decreased the consumption of sugar. Gestational
diabetes mellitus in women randomized to the TLC
group was significantly lower versus those receiving
standard care (23.3% vs 57.1%, P = 0.009).
In the RCT by Xiaopei et al,27 pregnant women with
GDM were randomly selected to receive an intensive
treatment regimen that included one-to-one education,
lifestyle intervention, clinic visits, strict glucose control,
and frequent glucose self-monitoring. The standard
therapeutic regimen included group education on the
importance of proper diet, exercise, and self-monitoring
of glucose level. Patients receiving intensive treatment
had lower 30-minute glucose levels after 75-g glucose
load (8.26 [1.85] vs 9.46 [2.74] mmol/L), a smaller
waist circumference (75.8 [3.1] vs 78.3 [4.2] cm), and
healthier outcomes for the neonates as reduced preterm
delivery (2.4% vs 8.3%) and neonatal care admission
(21.3% vs 33.3%).
DIETARY SUPPLEMENTS
Inositols
Inositol belongs to vitamin B complex, and its
main source comes from the diet. Epimerization of
the 6-hydroxyl groups of inositol leads to the forma-
tion of 9 stereoisomers, including MYO and DCI,
both applied as insulin sensitizer drugs.
Biochemical studies have suggested that impair-
ment in insulin message could be due to a defect
in the inositol phosphoglycans (IPGs) second mes-
sengers.43,44 Inositol phosphoglycans are known to
have a role in activating enzymes that control glucose
metabolism.45,46
Most tissues through a membrane-associated sodium-
dependent inositol cotransporter take up circulatinguthorized reproduction of this article is prohibited.
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Copyright © 2014 Lippincott Williams & Wilkins. Unafree MYO; inositol uptake is inhibited by glucose.47
In particular, MYO had 10 times more affinity for
the transporter compared with DCI.48 D chiro-inositol
is synthesized by an epimerase that converts MYO
into DCI, with each tissue having its own particular
conversion rate, likely because of the specific needs
for the 2 different molecules.49,50
The binding between insulin and its receptor medi-
ates the production of low-molecular-weight IPGs
that act as secondary messengers of insulin action.
Hence, both MYO and DCI lead to a decrease in
blood glucose levels.Myo-inositol
In our review, we found 3 RCTs on the efficacy of
prevention of GDM with MYO supplementation.
The MYO supplementation was performed at the
same dose and with the same compound in all studies
(MYO 2 g + folic acid 200 mg, twice daily). Placebo
was used in none of them. In all studies, the control
arm was represented by treatment with 400 g/d of
folic acid.
D’Anna et al28 evaluated whether MYO supple-
mentation during pregnancy was able to reduce the
GDM diagnosis in women at high risk because of a
positive family history of type 2 diabetes mellitus.
The main outcome was the rate of GDM, which oc-
curred significantly more in women assigned to the
control group (15.3% vs 6.1%, P = 0.04; OR, 0.35
[CI, 0.13 to 0.96]). Moreover, the mean birth weight
and the number of babies with birth weight of greater
than 4000 g were significantly higher in the control
group, whereas preterm delivery and gestational hy-
pertension were similar.
Adverse events were not analyzed.
In the study by Matarelli et al,29 the authors evalu-
ated the effects of MYO supplementation in women
with elevated fasting glucose since the first/early
second trimester.
The group of those allocated to receive MYO had a
lower incidence of GDM (6% vs 71%, P = 0.001;
OR, 0.13; 95% CI, 0.03 to 0.50). The fetal abdominal
circumference measured at oral glucose tolerance test
time (MYO, 41.7 [17.9], vs controls, 65.6 [22.1]; P =
0.001) and the birth weight (MYO, 42.8 [20.4], vs
controls, 56.6 [25.9]; P = 0.001), both expressed as
percentiles, were lower in the MYO group. None of
the babies born in the MYO group experienced neo-
natal hypoglycemia, whereas this occurred in 10 of
the control group (P = 0.038).
Assumption of MYO was not associated with any
serious AE.uthorized reproduction of this article is prohibited.
677Interventions in Preventing GDM • CME Review ArticleCorrado et al30 conducted an RCT involving women
affected by newly discovered GDM. They were ran-
domized (1:2). After 8 weeks, fasting insulin (MYO,
from 31.2 [7.1] to 19.0 [5.8] mIU/mL; controls, from
33.9 [5.3] to 26.0 [6.8] mIU/mL; P < 0.05) and glu-
cose (MYO, from 5.5 [0.3] to 4.6 [0.3] mmol/L; con-
trols, from 5.4 [0.2] to 5.1 [0.3] mmol/L; P < 0.05)
levels decreased in both groups.
Adverse events were not analyzed.PROBIOTICS
The World Health Organization defines probiotics
as “microorganisms … able to confer defined health
benefits on the host.”51
Most probiotic products are either in food items
or supplied as dietary supplements. These products
vary considerably in their microbial composition and
number of viable bacteria.
The endogenous intestinal microflora of the human
being is an “organ” necessary to provide nourishment,
regulate the epithelial development, and instruct in-
nate immunity. In fact, the gut microbiome (“intesti-
nal flora”), composed of trillions of nonpathogenic
microorganisms usually commensal, serves as a filter
for the largest environmental exposure to which we
are exposed, that is, what we eat.52
Several biological studies demonstrate that probio-
tics can constantly modulate the gastrointestinal immune
system and thus the systemic low-grade inflammation
state because of the changes that the probiotic deter-
mines on the inflammatory response.53–56
Obesity57 and type 2 diabetes55 are associated with
divergent changes in the gut microbiome.
Several trials conducted in humans with type 2 dia-
betes showed a preservation of insulin sensitivity as
well as improvements in glycemia and lipids.56,58,59
Women with GDM are known to be at high risk for
developing type 2 diabetes and have a similar abnormal
insulin resistance and alteration in lipid metabolism.4
In our review, we found 2 RCTs on the efficacy of
prevention of GDM with probiotics supplementation.
In the prospective RCT by Laitinen et al,31 women
at the first trimester of pregnancy were randomized
to receive nutrition counseling to modify dietary in-
take or as controls; the dietary intervention group
was further randomized to receive probiotics (diet/
probiotics) or placebo (diet/placebo) in a double-
blind manner, and the control group received placebo
(control/placebo).
Blood glucose concentrations were lowest in the
diet/probiotics group during pregnancy (baseline-
adjusted means: 4.45, 4.60, and 4.56 mmol/L in theCopyright © 2014 Lippincott Williams & Wilkins. Unadiet/probiotics, diet/placebo, and control/placebo, re-
spectively; P = 0.025). Better glucose tolerance in the
diet/probiotics group was confirmed by a reduced
risk for elevated glucose concentration compared
with the control/placebo group (OR, 0.31 [95% CI,
0.12 to 0.78]; P = 0.013) as well as by the lowest insu-
lin concentration (adjusted means, 7.55, 9.32, and 9.27
mU/L; P = 0.032) and homeostatic model assessment
(adjusted means, 1.49, 1.90, and 1.88; P = 0.028)
and the highest quantitative insulin sensitivity check
index (adjusted means, 0.37, 0.35, and 0.35; P =
0.028) during the last trimester of pregnancy. The
effects observed extended during the 12-month post-
partum period.
On initiation of capsule consumption, 7% of the
women in the diet/probiotics group versus 8% in the
diet/placebo group and 3% in the control/placebo
group reported gut-associated AE; subsequently, the
prevalence of reported symptoms was reduced to
2% and 0.5% at subsequent study visits.
In the RCT conducted by Ansemi et al,32 primi-
gravida pregnant women with singleton pregnancy
at their third trimester were randomized to receive
200 g/d of conventional yogurt or the probiotic yogurt.
It was a commercially available product prepared with
the starter cultures of Streptococcus thermophilus and
Lactobacillus bulgaricus, enriched with probiotic cul-
ture of 2 strains of lactobacilli and bifidobacteria.
Significant differences were found comparing changes
in these variables between probiotic and conventional
yogurts (changes from baseline in serum insulin
levels: +1.2 [1.2] vs +5.0 [1.1] mIU/mL, respectively;
P = 0.02; and homeostatic model assessment score,
0.2 [0.3] vs 0.7 [0.2], respectively; P = 0.01). Con-
sumption of probiotic yogurt did not influence fasting
plasma glucose compared with conventional yogurt.
Consumption of probiotic yogurts was not associ-
ated with any serious AE.DISCUSSION
Although there were a relatively high number of re-
ports addressing the efficacy of the various approaches
to prevent GDM before or during pregnancy, few of
the studies analyzed reached a high-quality score.
As far as preconceptional intervention, every inter-
national guideline advises weight loss before both
ART and non-ART conception, in obese women.60,61
Data from observational and small intervention stud-
ies suggested that reduction in weight increases the
chances of conception, decreases pregnancy complica-
tions, and improves perinatal outcome.39,62 The only
available trial actually provided the first preliminaryuthorized reproduction of this article is prohibited.
678 Obstetrical and Gynecological Surveyevidence to support the efficacy of lifestyle treatment
in reducing total and central adiposity. Unfortunately,
no data on GDM or any other pregnancy complication
have been reported.
Exercise started early in pregnancy seems to lower
the risk for developing GDM in previous prospective
cohort, retrospective case-control, or cross-sectional
studies.63–66 Results from RCTs, however, indicated
no significant difference in GDM incidence between
women receiving an additional exercise and those re-
ceiving routine care.19–23 Such discrepant findings
could be related to design and size of the studies.
The only RCT reporting an improvement in maternal
glucose tolerance was performed with a reduced glu-
cose load (50 g), suggesting that physical intervention
alone has limited possibility to improve metabolism.19
Anyway, on the basis of the limited data, current evi-
dence cannot guide practice.
Several trials have been aimed at reducing both GDM
and GWG through dietary interventions (restrictions),
and data have recently been reported in systematic
reviews and/or meta-analyses.9,10,63,64 Interventions
were so diverse and inclusion criteria were so hetero-
geneous that no definite conclusions could be drawn.
To prevent maternal and neonatal complications, the
Institute of Medicine recommends a GWG between
5 and 9 kg (11 to 20 lbs) for obese women. However,
only approximately one third of subjects and even less
among obese women reached a weight gain in line
with Institute of Medicine recommendations.67 The
additional RCTs we evaluated are not of high quality,
still reported controversial results, and did not shed
light on the effectiveness of dietary restriction as the
single intervention to prevent GDM.
It has been proposed that this lack of effectiveness
may be related also to the fact that psychological factors
were not sufficiently considered.68 Pregnant women
with elevated levels of stress and anxiety consume
more fats, oils, sweets, and snacks as well as have
decreased intakes of vitamins,69 and some researches
demonstrated a positive correlation between prepre-
gnancy BMI, GWG, anxiety, and depressive symptoms,
suggesting an association between weight status and
psychosocial vulnerability.70–72
On the other hand, a multitargeted approach was
analyzed in several RCTs in which a lifestyle inter-
vention program in obese pregnant women included
diet counseling, PA, and sometimes psychological
assistance. In every study, the authors observed a re-
duced GWG in obese women receiving intervention,
compared with standard care. Noteworthy, a reduction
in GDMwas observed in 9 of the 13 trials we analyzed.
In addition, lifestyle intervention was associated withCopyright © 2014 Lippincott Williams & Wilkins. Unaa reduction in gestational hypertension and preterm
delivery rates, whereas considerable heterogeneity
was found in terms of birth weight and fetal macrosomia
occurrence.
Considering dietary supplements, data seem to in-
dicate that the use of MYO could be beneficial on
the glucose/insulin homeostasis in pregnancy, and it
is associated with a reduction in GDM onset. This
finding has been confirmed in a preliminary report
of another trial that included women with a BMI of
greater than 27.73 Thus, these few evidences seem
to suggest a role for MYO supply in the prevention
of GDM, in different categories of women at risk.
Moreover, 2 of the studies also reported that MYO-
treated women gave birth to babies of reduced weight
compared with controls.
On the other hand, probiotic supplementation,
either alone or in combination with pharmacological
and nonpharmacological interventions, is a further area
of research in the prevention of GDM. The results from
the available RCTs suggest that probiotics may re-
duce the risk for GDM, a conclusion in line with the
recent Cochrane Review.74 As reported for MYO,
there was a reduction in birth weight in the women
taking probiotics.CONCLUSIONS
Implementing prevention requires the knowledge
of the mechanisms allowing the target disorders. This
condition is not fully reached in the case of GDM al-
though we all are aware of the risk factors. Indeed,
studieswere directed toward the correction of energy bal-
ance through both appropriate qualitative/quantitative
intake and stimulating energy expenditure.
Trials in which only intake or expenditure has been
targeted mostly reported negative results. On the
contrary, combined lifestyle programs including diet
control (orienting food intake, restricting energy in-
take) associated with moderate but continuous PA
exhibit better efficacy in reducing GDM prevalence.
The results from dietary supplements with MYO
or probiotics are promising. The actual evidences
provide enough arguments for implementing large-
scale, high-quality RCTs looking at the possible ben-
efits of these new approaches for preventing GDM.
Generally speaking, one issue is represented by the
heterogeneous prescriptions that have been applied in
the different reports and that cannot be easily stan-
dardized. Another issue is represented by women’s
compliance.
Indeed, changing habits even for a limited period is
not an easy task. In this respect, health providers needuthorized reproduction of this article is prohibited.
679Interventions in Preventing GDM • CME Review Articleto produce similar efforts and investments as already
done for smoking cessation. Obstetricians should be
aware and therefore disseminate the concept that
the gestational period is so crucial for the health of
the next generation.REFERENCES
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